At the 2010 American Society of Clinical Oncology Annual Meeting, ipilimumab(an anti-human CTLA-4 antibody) was reported to extend the overall survival in patients with advanced melanoma by 10months, and an important study showed considerable therapeutic benefit in combining anti-CTLA-4 and anti-Tim-3 to control CT26 colon adenocarcinoma20. Here, HAVCR2 is linked to melanoma.